EMA Authorised: Triumeq (dolutegravir sodium;lamivudine;abacavir (as sulfate)) — ViiV Healthcare B.V.

View source ↗

Summary

The EMA has authorised Triumeq, a fixed-dose combination of dolutegravir, lamivudine, and abacavir, for treating HIV infection. The product is manufactured by V…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dolutegravir (dolutegravir)
• Lamivudine (lamivudine)
• abacavir (abacavir)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: ViiV Healthcare B.V.. Decision date: 23/01/2026